Bemnifosbuvir / Ruzasvir
Hepatitis C Virus (HCV)
Phase 3Active
Key Facts
About Atea Pharmaceuticals
Atea Pharmaceuticals is a Boston-based biotech focused on discovering and developing oral antiviral therapies for RNA viruses, leveraging a proprietary platform of purine nucleos(t)ide prodrugs. Its lead asset, a combination of bemnifosbuvir (polymerase inhibitor) and ruzasvir (NS5A inhibitor), is in Phase 3 development for hepatitis C with topline data expected in 2026. Founded by antiviral veteran Jean-Pierre Sommadossi, the company's strategy targets significant unmet needs in HCV and other RNA viral diseases with convenient oral regimens designed for high efficacy and a high barrier to resistance.
View full company profile